Related Experiment Videos
The relationship between computerized physician order entry and pediatric adverse drug events: a nested matched
Feliciano Yu1, Maribel Salas, Young-Il Kim
1Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Pharmacoepidemiology and Drug Safety
|May 30, 2009
Summary
Computerized Physician Order Entry (CPOE) significantly reduces adverse drug events (ADEs) in pediatric hospitals. Implementing CPOE systems is associated with a 42% decrease in reportable ADEs, enhancing patient safety.
Area of Science:
- Health Informatics
- Pediatric Patient Safety
- Pharmacovigilance
Background:
- Adverse Drug Events (ADEs) pose a significant risk in pediatric healthcare settings.
- Computerized Physician Order Entry (CPOE) systems are increasingly adopted to improve medication safety.
- The impact of CPOE on ADEs in pediatric populations requires further investigation.
Purpose of the Study:
- To evaluate the association between CPOE implementation and the incidence of reported ADEs in pediatric hospitals.
- To quantify the effect of CPOE on ADE rates, controlling for patient and hospital characteristics.
Main Methods:
- A nested matched case-control study design was employed.
- Data on CPOE implementation were obtained from the Health Information Management Systems Society Analytics database.
- Reported ADE data were sourced from the National Association of Children's Hospitals and Related Institutions Case Mix Comparative Data Program.
- Univariate and multivariate conditional logistic regression analyses were used to examine differences.
Main Results:
- Patients in CPOE-equipped hospitals were more likely to be in larger facilities with greater comorbidity burdens.
- When matched by diagnosis, age, gender, and race, ADE cases showed higher comorbidity rates.
- Hospitals utilizing CPOE reported ADEs less frequently.
- Patients in non-CPOE hospitals were 42% more likely to experience reportable ADEs after adjusting for comorbidities.
Conclusions:
- CPOE adoption demonstrates a significant beneficial association with reduced reportable ADEs in pediatric hospitals.
- Implementation of CPOE systems is a key strategy for enhancing medication safety in pediatric care.
- Findings support the widespread adoption of CPOE to mitigate ADE risks in children.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...